Should eligibility for heart transplantation be a requirement for left ventricular assist device use? Recommendations based on a systematic review

Canadian Journal of Cardiology

Volumn 29, Issue 12, 2013, Pages 1712-1720

  Boothroyd, Lucy J ^a   Lambert, Laurie J ^a   Sas, Georgeta ^a   Guertin, Jason R ^a   Ducharme, Anique ^b   Charbonneau, Éric ^c   Carrier, Michel ^b   Cecere, Renzo ^d   Morin, Jean E ^a,d   Bogaty, Peter ^a,c  

^a Institut National d'Excellence en Sante et en Services Sociaux INESSS   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE;

BRIDGE TO TRANSPLANTATION; CARDIOVASCULAR PROCEDURE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DESTINATION THERAPY; ECONOMIC EVALUATION; HEALTH CARE COST; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; REVIEW; SIMULATION; SYSTEMATIC REVIEW;

CANADA; COST-BENEFIT ANALYSIS; ELIGIBILITY DETERMINATION; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; SURVIVAL ANALYSIS;

EID: 84888303670     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.05.014     Document Type: Review

References (41)

1. Birks E.J. The comparative use of ventricular assist devices: differences between Europe and the United States. Tex Heart Inst J 2010, 37:565-567.
2. Réseau Québécois de Cardiologie Tertiaire (RQCT). Rapport du groupe de travail: utilisation des dispositifs d'assistance ventriculaire (DAV). Montreal, QC: Réseau québécois de cardiologie tertiaire; 2010. Available at: Accessed March 11, 2013 [in French]. http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2010/10-906-07F.pdf.
3. Pagani F.D., Miller L.W., Russell S.D., et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. JAm Coll Cardiol 2009, 54:312-321.
4. Starling R.C., Naka Y., Boyle A.J., et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). JAm Coll Cardiol 2011, 57:1890-1898.
5. Petrucci R.J., Wright S., Naka Y., et al. Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. JHeart Lung Transplant 2009, 28:542-549.
6. Kamdar F., Boyle A., Liao K., Colvin-Adams M., Joyce L., John R. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients. JHeart Lung Transplant 2009, 28:352-359.
7. Russell S.D., Rogers J.G., Milano C.A., et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009, 120:2352-2357.
8. Slaughter M.S., Naka Y., John R., et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. JHeart Lung Transplant 2010, 29:616-624.
9. Kugler C., Malehsa D., Tegtbur U., et al. Health-related quality of life and exercise tolerance in recipients of heart transplants and left ventricular assist devices: A prospective, comparative study. JHeart Lung Transplant 2011, 30:204-210.
10. Strueber M., O'Driscoll G., Jansz P., Khaghani A., Levy W.C., Wieselthaler G.M. Multicenter evaluation of an intrapericardial left ventricular assist system. JAm Coll Cardiol 2011, 57:1375-1382.
11. Popov A.F., Hosseini M.T., Zych B., et al. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg 2012, 93:810-815.
12. Aaronson K.D., Slaughter M.S., Miller L.W., et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012, 125:3191-3200.
13. Slaughter M.S., Rogers J.G., Milano C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. NEngl J Med 2009, 361:2241-2251.
14. Park S.J., Milano C.A., Tatooles A.J., et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012, 5:241-248.
15. Petrucci R.J., Rogers J.G., Blue L., et al. Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support. JHeart Lung Transplant 2012, 31:27-36.
16. Kirklin J.K., Naftel D.C., Kormos R.L., et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. JHeart Lung Transplant 2012, 31:117-126.
17. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?. JThorac Cardiovasc Surg 2012, 144:584-603. [discussion: 597-8].
18. INTERMACS Quarterly Statistical Report: December 31, 2012 Report 2012 4th Quarter. Exhibit 14. Available at: Accessed April 9, 2013. http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Statistical_Summaries/Federal_Partners_Report_2012_Q4.pdf.
19. Daneshmand M.A., Rajagopal K., Lima B., et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann Thorac Surg 2010, 89:1205-1209. [discussion: 10].
20. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. NEngl J Med 2001, 345:1435-1443.
21. Lindenfeld J., Feldman A.M., Saxon L., et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association Class IV heart failure. Circulation 2007, 115:204-212.
22. Rogers J.G., Aaronson K.D., Boyle A.J., et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. JAm Coll Cardiol 2010, 55:1826-1834.
23. Moreno S.G., Novielli N., Cooper N.J. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. JHeart Lung Transplant 2011, 31:450-458.
24. Rogers J.G., Bostic R.R., Tong K.B., Adamson R., Russo M., Slaughter M.S. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 2012, 5:10-16.
25. Goyal S., Dubé L. Thoratec Heartmate II - destination therapy: rapport d'évaluation du BETMIS 2012, Bureau d'évaluation des technologies et des modes d'intervention en santé (BETMIS), Institut de cardiologie de Montréal, Montreal, QC.
26. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada, 3rd Ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Available at: Accessed April 8, 2013. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf.
27. Gold M.R., Siegel J.E., Russell L., Weinstein M. Cost-Effectiveness in Health and Medicine 1996, Oxford University Press, New York.
28. Simoens S. How to assess the value of medicines?. Front Pharmacol 2010, 1:115.
29. Institut national d'excellence en santé et en services sociaux (INESSS). Projet pilote sur l'évaluation de quatre médicaments anticancéreux. Montreal: INESSS, 2011. Available at: Accessed March 11, 2013 [in French]. http://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/ProjetPilote_Cancer/Document_synthese_final_CAV.pdf.
30. McKelvie R.S., Moe G.W., Cheung A., et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011, 27:319-338.
31. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
32. Lockard K.L., Weimer A., O'Shea G., Driggers E., Conroy L., Teutenberg J.J. The Joint Commission's disease-specific care certification for destination therapy ventricular assist devices. Prog Transplant 2010, 20:155-162.
33. Slaughter M.S. Will destination therapy be limited to large transplant centers?. Tex Heart Inst J 2010, 37:562-564.
34. Institut national d'excellence en santé et en services sociaux (INESSS). Évaluation des données probantes sur les dispositifs d'assistance ventriculaire HeartMate II® et HeartWare® pour le traitement de l'insuffisance cardiaque chronique terminale. Montreal, QC, 2012. Available at: Accessed March 11, 2013 [in French]. http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Cardio/ETMIS2012_Vol8_No15.pdf.
35. Eshelman A.K., Mason S., Nemeh H., Williams C. LVAD destination therapy: Applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev 2009, 14:21-28.
36. Brush S., Budge D., Alharethi R., et al. End-of-life decision-making and implementation in recipients of a destination left ventricular assist device. JHeart Lung Transplant 2010, 29:1337-1341.
37. Allen L.A., Stevenson L.W., Grady K.L., et al. Decision-making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012, 125:1928-1952.
38. Rizzieri A.G., Verheijde J.L., Rady M.Y., McGregor J.L. Ethical challenges with the left ventricular assist device as a destination therapy. Philos Ethics Humanit Med 2008, 3:20.
39. Petrucci R.J., Benish L.A., Carrow B.L., et al. Ethical considerations for ventricular assist device support: a 10-point model. ASAIO J 2011, 57:268-273.
40. Haute Autorité de Santé (HAS). Évaluation de l'assistance circulatoire mécanique (hors dispositifs légers). Paris, France: HAS, 2008. Available at: Accessed March 11, 2013 [in French]. http://www.has-sante.fr/portail/upload/docs/application/pdf/rapport_assistance_ventriculaire.pdf.
41. Thoratec Corporation. HeartMate II Clinical Outcomes. 2013. Available at: Accessed February 19, 2013. http://www.thoratec.com/vad-trials-outcomes/clinical-outcomes/hm2-bridge-to-transplant.aspx.